Among patients with PD-L1 <1%, a relatively smaller OS benefit was observed in two of three SQ NSCLC studies reporting PD-L1 subgroup OS data (Table 4; Figure 6), and a relatively smaller PFS benefit was observed in all four studies reporting PD-L1 subgroup data (Table 4; Figure 7). This evidence concerns the gene CD274 and non-small cell lung carcinoma.